Biotechnological Method for Production of Recombinant Peptide Analgesic (Purotoxin-1) from Geolycosa sp. Spider Poison
Severe chronic and sometimes incurable diseases are frequently accompanied by a pain syndrome. Purotoxin-1, isolated from the poison of the Central Asian Geolycosa sp. spider and selectively inhibiting the purinergic P2X3 receptor (which is considered as a target for the control of the pain states), is one potentially highly effective drug with an analgesic effect. To produce the recombinant purotoxin-1, we created four genetically engineered constructions with different carrier proteins for the expression in E. coli: pTRX-PT1, pCBD-PT1, pGyrA-PT1, pDnaB-PT1. The construction with mini-intein DnaB from the Synechocystis sp. was the most efficient. Using the E. coli C3030/pDnaB-PT1 producer strain, the laboratory method, based on which a pilot technology of recombinant purotoxin-1 production was developed as a result of optimization and scaling, was created. Six grams of recombinant PT1 preparation with the confirmed pharmacological purity was developed for preclinical trials.
Keywordsproduction of recombinant proteins intein analgesic peptide toxin
part per million
reversed-phase highperformance liquid chromatography
Unable to display preview. Download preview PDF.
- 4.Vasilevskii, A.A., Savchenko, G.A., Korol’kova, Yu.V., Boichuk, Ya.A., Pluzhnikov, K.A., Kryshtal’, O.A., and Grishin, E.V., Peptide modulator of purinergic receptors, RF Patent no. 2422459, Byull. Izobret., 2011, no. 18.Google Scholar